Unknown Health Risks of Inhaled InsulinSeptember 2007
By T.R. Shantha, MD, PhD, FACA
Life Extension Magazine
By T.R. Shantha, MD, PhD, FACA
Fear of needles and the inconvenience of administering insulin injections have created a burgeoning demand for alternative methods of treating diabetes. An apparent breakthrough arrived with the development of an insulin preparation that required no needles, but instead could simply be inhaled.
While the FDA has deemed this novel insulin preparation safe and effective, many questions regarding its long-term health effects remain unresolved. Here, we discuss the use, safety, and potential risks of insulin inhalation preparations.
Insulin and the Etiology of Diabetes
Insulin is a hormone that is essential for human life. It works by interacting with the insulin receptors on cell membranes to facilitate the entry of glucose and other nutrients into cells for energy production. Insulin thus facilitates various cellular metabolic functions and promotes cell division, while removing excess sugar from the blood.
Type l diabetes is characterized by a lack of insulin in the blood due to lack of its production in the pancreas (specifically, in the islets of Langerhans). In type 2 diabetes, the pancreas does produce insulin, but the body’s cells are resistant to insulin’s action—it is as if the doors that allow glucose to move from the blood into the cells are shut. The result is high levels of unused insulin and glucose in the blood—the hallmarks of early-stage type 2 diabetes. In the later stages of type 2 diabetes, the pancreas fails to secrete enough insulin, and the patient becomes reliant on either drugs that artificially stimulate pancreatic insulin secretion, or on exogenously administered insulin.
Presently, type 1 diabetes is treated with daily insulin injections, whereas type 2 diabetes is treated with oral anti-diabetic pills, either alone or in combination with insulin shots. Other safe modalities to curtail, control, and cure diabetes are under intense research. The most recent innovation in diabetes management is the introduction of insulin for inhalation, rather than for injection.
Development of Inhaled Insulin to Treat Diabetes
Based on today’s epidemic of diabetes, there is a large and growing demand for insulin drugs. However, the pain, inconvenience, and disruption of lifestyle associated with multiple daily insulin injections leads many patients to abandon their doctor-recommended treatment plans. As a result, many patients fail to achieve effective management of their condition. To eliminate pain and improve patient compliance—and thus treatment outcomes—increasing research has focused on alternatives to subcutaneous (SC) insulin injections. Some of the areas of investigation include: aerosolized insulin for inhalation, oral insulin, insulin-producing stem cell implantation, and insulin delivery pumps.
The first inhalation insulin has now been approved for use in US and Europe, and numerous similar products are on the horizon. This novel device delivers a powdered form of insulin to the alveoli of the lungs, where, since the lung is a large microvascular organ, insulin is absorbed into the bloodstream.1
Distribution of Inhaled Insulin, Insulin Receptors, and Cancer
The inhaled form of insulin is effective only when the administered dose is three to ten times the amount given by subcutaneous injection, because little more than 10% of the inhaled insulin reaches the alveoli.2,3 The interval between the administration of insulin and the onset of glucose-lowering activity is about 10 to 20 minutes. Given its rapid onset of activity, inhaled insulin is suitable for preprandial (before meal) but not for long-term basal (baseline) use.
Tight glucose control, however, may come at a price. One area of potential concern regarding inhaled insulin is the possible effects on the tissues that it comes in contact with on its way to the alveoli, such as the linings of the mouth, throat, tongue, cheeks, gums, tonsils, trachea, bronchial tree, vocal cords, larynx, nose and nasal air sinuses, and olfactory mucosa (which has a direct connection to the brain). Furthermore, since insulin is a weak growth factor, there is also the potential concern that inhaled insulin could support aberrant cell growth, and potentially even trigger or support cancer.
Scientists have noted that those with elevated blood sugar due to type 2 diabetes and other conditions are more prone to develop certain types of cancers than the healthy population.4 Numerous cancers, and even non-cancerous fibrous tumors, have more than the normal amount of insulin receptors to facilitate the entry of large amounts of glucose into the tumor cells, thus promoting their growth, multiplication, and spread.5-10
Another important uncertainty about treatment with inhaled insulin is therefore the potentially increased risk of lung cancer. Studies of human bronchial epithelial cells suggest that insulin-receptor activation is in itself insufficient for malignant transformation. However, once malignant transformation has been induced by other agents, the insulin receptor pathway is thought to promote malignant progression of these cells.11
Since inhaled insulin comes in contact with so many tissues, it is crucial that future research examines its impact on normal, pre-cancerous, and cancerous cells of the upper respiratory and digestive systems.
Like what you are reading?
Sign up for exclusive offers, product suggestions, health tips & more!